July 7, 2020 / 4:13 PM / a month ago

BRIEF-GSK Says Long-Acting Injectable Cabotegravir 66% More Effective Than Truvada

July 7 (Reuters) - ViiV Healthcare:

* GSK’S VIIV - DATA SHOWS LONG-ACTING INJECTABLE CABOTEGRAVIR GIVEN EVERY TWO MONTHS 66% MORE EFFECTIVE VERSUS DAILY PILLS IN STOPPING HIV ACQUISITION

* VIIV HEALTHCARE - EFFICACY OF CABOTEGRAVIR COMPARED TO DAILY ORAL EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 200 MG AND 300 MG (FTC/TDF) TABLETS

* VIIV HEALTHCARE - LONG-ACTING CABOTEGRAVIR, FTC/TDF TABLETS BOTH WELL TOLERATED THROUGHOUT STUDY

* VIIV - MOST PARTICIPANTS IN CABOTEGRAVIR GROUP (80%) REPORTED PAIN OR TENDERNESS AT INJECTION SITE VERSUS 31% OF THOSE IN FTC/TDF ARM, WHO GOT PLACEBO

* VIIV HEALTHCARE - PLANS TO USE DATA FROM HPTN 083 FOR FUTURE REGULATORY SUBMISSIONS

* VIIV HEALTHCARE - MOST ADVERSE EVENTS OF STUDY MILD OR MODERATE IN NATURE AND BALANCED BETWEEN BOTH TREATMENT ARMS

* VIIV - STUDY CONDUCTED IN MEN WHO HAVE SEX WITH MEN, TRANSGENDER WOMEN WHO HAVE SEX WITH MEN; FURTHER STUDY BEING CONDUCTED IN SEXUALLY ACTIVE WOMEN Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below